167 related articles for article (PubMed ID: 38805059)
1. Contraceptive counseling for iPLEDGE and its burden on dermatologists.
Owens KE; Jiang SW; Nicholas MW
Arch Dermatol Res; 2024 May; 316(6):287. PubMed ID: 38805059
[TBL] [Abstract][Full Text] [Related]
2. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
3. Administrative Burden of iPLEDGE Deters Isotretinoin Prescriptions: Results From a Survey of Dermatologists.
Lee G; Wolf JR; Somers KE
Cutis; 2022 Jul; 110(1):44-47. PubMed ID: 36179224
[TBL] [Abstract][Full Text] [Related]
4. Women's experiences with isotretinoin risk reduction counseling.
Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
[TBL] [Abstract][Full Text] [Related]
5. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
6. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
Honein MA; Lindstrom JA; Kweder SL
Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
[TBL] [Abstract][Full Text] [Related]
7. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
[TBL] [Abstract][Full Text] [Related]
8. iPLEDGE Must Abstain from Abstinence.
Lowery K; Rosen T; Malek J
J Clin Aesthet Dermatol; 2020 Jun; 13(6):54-56. PubMed ID: 32884622
[TBL] [Abstract][Full Text] [Related]
9. Compliance with pregnancy prevention measures during isotretinoin therapy.
Collins MK; Moreau JF; Opel D; Swan J; Prevost N; Hastings M; Bimla Schwarz E; Korb Ferris L
J Am Acad Dermatol; 2014 Jan; 70(1):55-9. PubMed ID: 24157382
[TBL] [Abstract][Full Text] [Related]
10. Circumventing iPLEDGE: Circumventing ethical responsibility?
Lee KC; Bercovitch L
J Am Acad Dermatol; 2017 Dec; 77(6):1185-1187. PubMed ID: 29132856
[No Abstract] [Full Text] [Related]
11. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
12. Removal of Isotretinoin Gender-Based Guidelines: Inclusivity Takes Precedence.
Nanda S
Cutis; 2022 Mar; 109(3):E18-E20. PubMed ID: 35659135
[TBL] [Abstract][Full Text] [Related]
13. Isotretinoin, Patient Safety, and Patient-Centered Care-Time to Reform iPLEDGE.
Barbieri JS; Frieden IJ; Nagler AR
JAMA Dermatol; 2020 Jan; 156(1):21-22. PubMed ID: 31664426
[No Abstract] [Full Text] [Related]
14. Prescribing isotretinoin for transgender youth: A pledge for more inclusive care.
Boos MD; Ginsberg BA; Peebles JK
Pediatr Dermatol; 2019 Jan; 36(1):169-171. PubMed ID: 30318854
[TBL] [Abstract][Full Text] [Related]
15. Dermatologists' attitudes, prescription, and counseling patterns for isotretinoin: a questionnaire-based study.
Nagler AR; Orlow SJ
J Drugs Dermatol; 2015 Feb; 14(2):184-9. PubMed ID: 25689814
[TBL] [Abstract][Full Text] [Related]
16. The future of iPLEDGE: We pledge for more inclusive access to isotretinoin.
Shah N; Kirkorian AY
Pediatr Dermatol; 2021 Nov; 38 Suppl 2():183-184. PubMed ID: 34184311
[No Abstract] [Full Text] [Related]
17. Patient Access in Restrictive Risk Management Programs: The Case of iPLEDGE.
Kerr KW; Wosinska ME
Ther Innov Regul Sci; 2017 Jan; 51(1):16-23. PubMed ID: 30235995
[TBL] [Abstract][Full Text] [Related]
18. Promoting safe use of isotretinoin by increasing contraceptive knowledge.
Werner CA; Papic MJ; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Apr; 151(4):389-93. PubMed ID: 25650743
[TBL] [Abstract][Full Text] [Related]
19. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential.
AlGhamdi KM; Khurram H; Asiri YA; Mandil A
Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870
[TBL] [Abstract][Full Text] [Related]
20. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
